Stockholders Approve Massive Increase in Authorized Shares and Significant Warrant Issuances

summarizeSummary

Stockholders approved a massive increase in authorized shares from 6 million to 100 million, along with the issuance of over 2 million shares for warrant exercises and 100,000 shares for an equity plan, signaling extreme potential dilution to address the company's going concern.

check_boxKey Events

• Authorized Shares Increased to 100 Million

  Stockholders approved an amendment to the Articles of Incorporation, increasing the total authorized shares of common stock from 6,000,000 to 100,000,000. This enables the company to issue a significantly larger number of shares in the future, representing a potential increase of over 96 times the current outstanding shares.

• Approval for Issuance of 2.03 Million Warrant Shares

  Shareholders approved the issuance of up to 1,662,553 shares upon the exercise of common, placement agent, and pre-funded warrants, and an additional 368,471 shares upon the exercise of new unregistered common stock purchase warrants, both stemming from December 2025 agreements. This totals 2,031,024 shares, which could more than double the current outstanding shares upon exercise.

• Equity Incentive Plan Expanded by 100,000 Shares

  An amendment to the 2020 Equity Incentive Plan was approved, increasing the number of shares authorized for issuance under the plan by 100,000 shares. This adds to the potential future dilution from employee compensation.

• Addresses Going Concern Warning

  These approvals are critical steps for the company to raise necessary capital, following a recent 10-Q filing that included a 'going concern' warning due to insufficient cash for the next 12 months.

auto_awesomeAnalysis

Aethlon Medical's stockholders have approved several critical measures that pave the way for substantial future capital raises, but at the cost of extreme potential dilution for existing shareholders. The most impactful approval is the increase in authorized common stock from 6 million to 100 million shares. Given the company's current 973,213 outstanding shares, this represents a potential increase of over 96 times the current outstanding shares, enabling monumental future dilution. Additionally, shareholders approved the issuance of 2,031,024 shares upon the exercise of warrants related to a December 2025 financing agreement, which alone could more than double the current outstanding shares. An additional 100,000 shares were authorized for the equity incentive plan. These approvals are a necessary step for the company to address its previously disclosed 'going concern' warning, indicating a need for significant capital to continue operations. While crucial for survival, the scale of potential dilution is highly negative for current equity holders.